Intravenous Immunoglobulin (IVIG) Versus Plasma Exchange (PE) for Ventilated Children With Guillain Barre Syndrome (GBS)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Comparing whether intravenous immune globulin or plasma exchange is superior in treating mechanically ventilated children with Guillain Barre syndrome.
| Condition | Intervention |
|---|---|
|
Guillain Barre Syndrome |
Drug: IVIG Procedure: Plasma Exchange |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Comparison of Intravenous Immunoglobulin and Plasma Exchange in Treatment of Mechanically Ventilated Children With Guillain Barre Syndrome. A Randomized Study. |
- Duration of mechanical ventilation [ Time Frame: 21 days (average) ] [ Designated as safety issue: No ]How many days did the mechanical ventilation continue
- PICU stay [ Time Frame: 28 days (average) ] [ Designated as safety issue: No ]How many days did the child spend on PICU
- Ability to walk [ Time Frame: 4 weeks from PICU discharge ] [ Designated as safety issue: No ]Ability of the child to walk unaided at 4 weeks from PICU admission
| Enrollment: | 41 |
| Study Start Date: | January 2007 |
| Study Completion Date: | February 2010 |
| Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: IVIG group
20 children randomized to receive IVIG for 5 days at a dose of 0.4 g/kg/day
|
Drug: IVIG
Intravenous Immune Globulin at a dose 0f 0.4 g/kg/day for 5 consecutive days
Other Name: Sandglobin
|
|
Active Comparator: Plasma Exchange
21 children randomized to receive 5 sessions of 1 volume plasma exchange per day for 5 consecutive days
|
Procedure: Plasma Exchange
Five sessions of plasma exchange, single plasma volume each, for 5 consecutive days
Other Name: Plasmapheresis
|
Detailed Description:
Children with Guillain Barre syndrome (GBS) admitted to PICU at Mansoura University Children Hospital, Mansoura, Egypt with the need for mechanical ventilation were prospectively enrolled in the study.
Cases were diagnosed according to clinical criteria. The decisions to initiate, wean and terminate mechanical ventilation were made independently by the attending consultant in accordance with the unit guidelines.
Outcome variables measured were duration of mechanical ventilation, length of PICU stay and ability to walk unaided 4 weeks after PICU discharge.
Eligibility| Ages Eligible for Study: | 1 Month to 18 Months |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age: children from 1 month - 18 years old
- Clinical diagnosis of Guillain Barre syndrome
- Requirement of mechanical ventilation
Exclusion Criteria:
- Need for mechanical ventilation beyond 14 days from disease onset
- Child receiving IVIG or PE prior to enrollment
Contacts and Locations| Egypt | |
| Mansoura University Children Hospital | |
| Mansoura, Dakahlia, Egypt | |
| Principal Investigator: | Mohammed A El-Bayoumi, MD, FRCPCH | Head of PICU, Mansoura University Children Hospital |
More Information
No publications provided by Mansoura University Children Hospital
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Dr. Mohammed El-Bayoumi, MD, FRCPCH, Head of PICU - Mansoura University Children Hospital |
| ClinicalTrials.gov Identifier: | NCT01306578 History of Changes |
| Other Study ID Numbers: | MUCH-GBS |
| Study First Received: | March 1, 2011 |
| Last Updated: | March 1, 2011 |
| Health Authority: | Egypt: Institutional Review Board |
Keywords provided by Mansoura University Children Hospital:
|
Guillain Barre syndrome IVIG Plasma exchange |
Additional relevant MeSH terms:
|
Guillain-Barre Syndrome Polyradiculoneuropathy Autoimmune Diseases of the Nervous System Nervous System Diseases Demyelinating Diseases Peripheral Nervous System Diseases Neuromuscular Diseases Polyneuropathies Autoimmune Diseases |
Immune System Diseases Immunoglobulins Antibodies Immunoglobulins, Intravenous Rho(D) Immune Globulin Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on June 17, 2013